{"url_path":"/sec/rcel/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1762303/0001762303-26-000003-index.html","accession_number":"0001762303-26-000003","cik":"0001762303","ticker":"RCEL","issuer_name":"AVITA Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1762303/0001762303-26-000003-index.html","primary_entity_key":"0001762303","primary_entity_name":"AVITA Medical, Inc."},"word_count":843,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nAt the Annual Meeting, the Company’s stockholders voted on all the proposals summarized in the Proxy Statement, as set forth below:\n\n \n\n1.\nElection of Directors (Proposal 1): All seven directors named in the Proxy Statement were elected to serve on the Company’s Board of Directors with the following votes:\n\n \n\nName\n\nVotes For\n\n \n\nVotes Withheld\n\n \n\nBroker Non-Votes\n\n \n\nJan Stern Reed\n\n \n\n10,902,991\n\n \n\n \n\n798,914\n\n \n\n \n\n3,890,542\n\n \n\nProfessor Suzanne Crowe\n\n \n\n10,979,194\n\n \n\n \n\n722,711\n\n \n\n \n\n3,890,542\n\n \n\nJeremy Curnock Cook\n\n \n\n10,700,424\n\n \n\n \n\n1,001,481\n\n \n\n \n\n3,890,542\n\n \n\nRobert McNamara\n\n \n\n10,962,888\n\n \n\n \n\n739,017\n\n \n\n \n\n3,890,542\n\n \n\nDr. Michael Tarnoff\n\n \n\n11,011,908\n\n \n\n \n\n689,997\n\n \n\n \n\n3,890,542\n\n \n\nJoseph Woody\n\n \n\n10,977,874\n\n \n\n \n\n724,031\n\n \n\n \n\n3,890,542\n\n \n\nCary Vance\n\n \n\n11,176,792\n\n \n\n \n\n525,113\n\n \n\n \n\n3,890,542\n\n \n\n \n\n2.\nAppointment of Independent Auditor (Proposal 2): The stockholders ratified the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\n \n\n14,962,654\n\n \n\n \n\n255,151\n\n \n\n \n\n374,642\n\n \n\n \n\n3.\nIncrease the maximum aggregate annual cash fee pool from which the non-executive Directors of the Company may be paid (Proposal 3): Stockholders approved, for the purposes of ASX Listing Rule 10.17 and section 2.10 of the Company’s Amended and Restated Bylaws (and for all other purposes), an increase to the aggregate annual cash fee pool from which non-executive directors of the Company may be paid for their services from a maximum of US$750,000 per annum to a maximum of US$900,000 per annum. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n8,582,602\n\n \n\n \n\n2,710,656\n\n \n\n \n\n408,647\n\n \n\n \n\n3,890,542\n\n \n\n \n\n4.\nIssuance of Securities to Non-Executive Directors (Proposals 4 - 7, 9 & 11): Stockholders approved the annual grants comprised of 22,214 restricted stock units and 16,133 stock options, to each of the following non-executive directors, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding these proposals were as follows:\n\n \n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\nProfessor Suzanne Crowe\n\n \n\n8,869,562\n\n \n\n \n\n2,411,009\n\n \n\n \n\n421,334\n\n \n\n \n\n3,890,542\n\n \n\nJeremy Curnock Cook\n\n \n\n8,722,810\n\n \n\n \n\n2,544,450\n\n \n\n \n\n434,645\n\n \n\n \n\n3,890,542\n\n \n\nRobert McNamara\n\n \n\n8,818,589\n\n \n\n \n\n2,449,386\n\n \n\n \n\n433,930\n\n \n\n \n\n3,890,542\n\n \n\nJan Stern Reed\n\n \n\n8,841,764\n\n \n\n \n\n2,434,253\n\n \n\n \n\n425,888\n\n \n\n \n\n3,890,542\n\n \n\nDr. Michael Tarnoff\n\n \n\n8,774,530\n\n \n\n \n\n2,458,787\n\n \n\n \n\n468,588\n\n \n\n \n\n3,890,542\n\n \n\nJoseph Woody\n\n \n\n8,830,204\n\n \n\n \n\n2,446,817\n\n \n\n \n\n424,884\n\n \n\n \n\n3,890,542\n\n \n\n \n\n5.\nIssuance of Securities to Dr. Michael Tarnoff (Proposal 8): Stockholders approved the initial grant comprised of 26,250 restricted stock units and 19,063 stock options, to Dr. Michael Tarnoff, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n8,791,498\n\n \n\n \n\n2,433,367\n\n \n\n \n\n477,040\n\n \n\n \n\n3,890,542\n\n \n\n \n\n6.\nIssuance of Securities to Joseph Woody (Proposal 10): Stockholders approved the initial grant comprised of 40,547 restricted stock units and 29,446 stock options, to Mr. Joseph Woody, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n8,863,312\n\n \n\n \n\n2,395,376\n\n \n\n \n\n443,217\n\n \n\n \n\n3,890,542\n\n \n\n \n\n7.\nAdvisory Vote to Approve Compensation of Named Executive Officers (Proposal 12): Stockholders voted in favor of the non-binding advisory vote to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n8,918,272\n\n \n\n \n\n2,202,213\n\n \n\n \n\n581,420\n\n \n\n \n\n3,890,542\n\n \n\n \n\n8.\nAdvisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13): Stockholders voted in favor of the non-binding advisory vote to set the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\n \n\n \n\n \n\n \n\n1 Year\n\n \n\n2 Years\n\n \n\n3 Years\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n9,545,151\n\n \n\n \n\n924,743\n\n \n\n \n\n650,252\n\n \n\n \n\n581,759\n\n \n\n \n\n3,890,542\n\n \n\n \n\n9.\nApproval of the Issuance of Warrants (Proposal 14): Stockholders approved, for the purpose of ASX Listing Rule 7.1 (and all other purposes), the issuance of a warrant or warrants covering up to 650,000 shares of Common Stock, with a term of ten years (the “Warrants”), to Perceptive Credit Holdings V, LP (“Perceptive”), pursuant to the credit agreement between the Company and Perceptive, dated January 13, 2026. The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n9,322,532\n\n \n\n \n\n1,769,627\n\n \n\n \n\n609,746\n\n \n\n \n\n3,890,542\n\n \n\n \n\n10.\nApproval of the Issuance of Equity Securities (Proposal 15): Stockholders approved as a special resolution, for the purpose of ASX Listing Rule 7.1A (which allows the Company to seek stockholder approval to issue an additional 10% over the annual listing limit of 15% of its issued capital in a consecutive 12-month period) and all other purposes, the issue of Equity Securities (as defined in ASX Listing Rule 19.2) up to such additional 10% of the issued capital (at the time of issuance) of the Company (as calculated in accordance with ASX Listing Rule 7.1A.2). The votes regarding this proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\n \n\n8,947,195\n\n \n\n \n\n2,223,106\n\n \n\n \n\n531,604\n\n \n\n \n\n3,890,542\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAVITA Medical, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 4, 2026\n\nBy:\n\n/s/ David O’Toole\n\n \n\n \n\n \n\nDavid O’Toole\nChief Financial Officer"}